van de Giessen, E
Weinstein, J J
Cassidy, C M
Haney, M
Dong, Z
Ghazzaoui, R
Ojeil, N
Kegeles, L S
Xu, X
Vadhan, N P
Volkow, N D
Slifstein, M
Abi-Dargham, A
Article History
Received: 4 August 2015
Revised: 29 January 2016
Accepted: 2 February 2016
First Online: 22 March 2016
Competing interests
: Dr Haney has received partial salary support for investigator-initiated studies from Insys Therapeutics Inc and Lifeloc Technologies and has served as a consultant to Aelis Farma and Health Advances LLC. Dr Kegeles has received research support from Amgen. Dr Slifstein has received research support from Forest Laboratories, Pierre-Fabre, CHDI, and Otsuka and has provided consultation for Amgen. Dr Abi-Dargham has received research support from Takeda and Forest Pharmaceuticals and has served on advisory boards for Roche, Forum, and Otsuka. The remaining authors declare no conflict of interests.